BioLineRx's GLIX1 Shows Synergy With PARP Inhibitors in Preclinical Ovarian Cancer StudiesPUBT·Oct 23, 2026 at 11:01 AMBLRX0.00%
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day | BLRX Stock NewsStockTitan·Oct 8, 2026 at 03:00 AMBLRX0.00%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Sep 30, 2026 at 09:05 PMADGM0.00%BLRX0.00%
BioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGMTip Ranks·Sep 24, 2026 at 08:27 PMBLRX0.00%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Sep 10, 2026 at 12:06 PMCDT0.00%SLXN0.00%
BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026PUBT·Sep 10, 2026 at 11:02 AMBLRX0.00%
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant DealTip Ranks·Aug 31, 2026 at 02:57 PMBLRX0.00%
BLRX: GLIX1 shows strong clinical progress and financials remain stable with cash runway into 2027Quartr·Aug 31, 2026 at 02:16 PMBLRX0.00%
